8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

April 1, 2008
_________________________________________________
Date of Report (Date of earliest event reported):

ACCELR8 TECHNOLOGY CORPORATION
_____________________________________________________

(Exact name of registrant as specified in charter)

__Colorado__________	_____0-11485________	____84-1072256___
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of incorporation)		Identification No.)

7000 North Broadway, Building 3-307, Denver, CO 80221
________________________________________________________
(Address of principal executive offices)

(303) 863-8808
______________________________________________________
Registrant’s telephone number, including area code:

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
	CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
	CFR 240.13e-4(c))

Item 8.01 Other Events.

     On April 1, 2008, Accelr8 Technology Corporation issued a press release announcing it had agreed in principle with Becton, Dickinson and Company (“BD”) to terms for an agreement with respect to Accelr8’s BACcel™ rapid bacterial diagnostic system. Under the contemplated agreement, BD will fund an 18-month milestone project starting April 1, 2008.

     BD will also have the option to license the technology for product development, manufacturing, and commercialization for the clinical diagnosis of infectious diseases.

The definitive agreement is expected to be signed before April 30, 2008.

A copy of the press release is attached as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits.
Exhibit No.	Description
99,1	Press Release dated as of April 1, 2008, announcing agreement in principal with BD

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 1, 2008	ACCELR8 TECHNOLOGY CORPORATION
	By:  /s/  Thomas V. Geimer
	Thomas V. Geimer, Chief Executive Officer

EX-99.1

Exhibit 99.1

Accelr8 and BD Agree on Terms for Technology Development Program for the BACcel™ Rapid Diagnostics Platform

DENVER, Colo., April 1, 2008 – Accelr8 Technology Corporation (Amex:AXK) announced today that BD (Becton, Dickinson and Company) and Accelr8 have agreed in principle to terms for an agreement with respect to Accelr8’s BACcel™ rapid bacterial diagnostic system. Under the contemplated agreement, BD will fund an 18-month milestone project starting April 1, 2008.

BD will also have the option to license the technology for product development, manufacturing, and commercialization for the clinical diagnosis of infectious diseases.

The definitive agreement is expected to be signed before April 30, 2008.

According to David Howson, Accelr8’s president, “BD leads the industry in clinical microbiology, with broad product offerings for classical microbiology as well as molecular diagnostics. We are excited to work with BD as we move into our next phase of BACcel development.”

In other news, Accelr8 noted issuance of its core “Quantum Microbiology™” patent, for which the company previously had announced notice of allowance. Additionally, the company noted acceptance of three scientific presentations for the 108th General Meeting of the American Society for Microbiology (ASM, www.asm.org) to be held June 1-5 in Boston, MA. Subjects to be covered include multiplexed identification of multiple drug resistance mechanisms, rapid Acinetobacter immunoassay performance, and quantitative analysis of bacteria extracted directly from human clinical specimens.

About Accelr8

Accelr8 Technology Corporation (www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing the BACcel™ rapid diagnostic system, based on its innovative surface coatings, assay processing, and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8’s own products.

Certain statements in this news release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forwardlooking statements, whether as a result of new information or future events.

Contact

John Metzger, Metzger Associates Tom Geimer, Accelr8 Technology Corp.
 +1.303.786.7000, ext. 2202 +1.303.863.8088
john@metzger.com tom.geimer@accelr8.com